Bloomberg Law
Drug, Device Manufacturers to Face Hill Scrutiny in 2019
January 8, 2019
Combating high drug and device prices is a bipartisan goal in Congress, and House Democrats in control of key oversight committees have made clear their plans to pursue investigations putting pharma CEOs under scrutiny. Manufacturers need to prep now to explain policies and prepare for public relations issues.
Contacts
Capabilities
Suggested News & Insights
Sidley Secures Plan Confirmation in Prospect Medical Holdings' US$2.3 Billion Chapter 11 CaseDecember 17, 2025BIOSECURE Act Included in the FY2026 National Defense Authorization ActDecember 12, 2025U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025Sidley Represents Lumexa Imaging in US$462.5 Million Initial Public OfferingDecember 10, 2025First Circuit Clarifies Application of Medicare’s “Reasonable and Necessary” Standard in FCA Cases Against Clinical LabsDecember 8, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory